EA202090019A1 - Спироциклические индолины в качестве модуляторов il-17 - Google Patents

Спироциклические индолины в качестве модуляторов il-17

Info

Publication number
EA202090019A1
EA202090019A1 EA202090019A EA202090019A EA202090019A1 EA 202090019 A1 EA202090019 A1 EA 202090019A1 EA 202090019 A EA202090019 A EA 202090019A EA 202090019 A EA202090019 A EA 202090019A EA 202090019 A1 EA202090019 A1 EA 202090019A1
Authority
EA
Eurasian Patent Office
Prior art keywords
modulators
spyrocyclic
indolins
oxoindoline
analogs
Prior art date
Application number
EA202090019A
Other languages
English (en)
Inventor
Гарет Нил Брейс
Роуз Элизабет Чеппелл
Эрве Жан Клод Дебов
Анна Мари Фоули
Грегори Фоулкс
Элизабет Перл Джонс
Фабьен Клод Леконт
Джоанна Рейчел Куинси
Моника-Зара Элизабет Доротея Шульце
Мэттью Данкан Селби
Адам Питер Смолли
Ричард Дэвид Тейлор
Роберт Джеймс Таунсенд
Чжаонин Чжу
Original Assignee
Юсб Байофарма Срл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юсб Байофарма Срл filed Critical Юсб Байофарма Срл
Publication of EA202090019A1 publication Critical patent/EA202090019A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

В заявке описана серия замещенных спироциклических производных 2-оксоиндолина и их аналогов, которые являются активными модуляторами активности IL-17 человека и поэтому полезны для лечения и/или предупреждения различных заболеваний человека, включая воспалительные и аутоиммунные нарушения.
EA202090019A 2017-06-14 2018-06-12 Спироциклические индолины в качестве модуляторов il-17 EA202090019A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1709456.6A GB201709456D0 (en) 2017-06-14 2017-06-14 Therapeutic agents
PCT/EP2018/065558 WO2018229079A1 (en) 2017-06-14 2018-06-12 Spirocyclic indolines as il-17 modulators

Publications (1)

Publication Number Publication Date
EA202090019A1 true EA202090019A1 (ru) 2020-05-20

Family

ID=59358375

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090019A EA202090019A1 (ru) 2017-06-14 2018-06-12 Спироциклические индолины в качестве модуляторов il-17

Country Status (10)

Country Link
US (1) US11052076B2 (ru)
EP (1) EP3638227B1 (ru)
JP (1) JP7163379B2 (ru)
CN (1) CN110769821B (ru)
BR (1) BR112019026678A2 (ru)
CA (1) CA3064156A1 (ru)
EA (1) EA202090019A1 (ru)
ES (1) ES2929369T3 (ru)
GB (1) GB201709456D0 (ru)
WO (1) WO2018229079A1 (ru)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3740478B1 (en) 2018-01-15 2023-11-01 UCB Biopharma SRL Fused imidazole derivatives as il-17 modulators
US11458124B2 (en) 2018-07-12 2022-10-04 UCBBiopharma Srl Spirocyclic indane analogues as IL-17 modulators
GB201820166D0 (en) 2018-12-11 2019-01-23 Ucb Biopharma Sprl Therapeutic agents
GB201820165D0 (en) 2018-12-11 2019-01-23 Ucb Biopharma Sprl Therapeutic agents
US11377425B1 (en) 2018-12-19 2022-07-05 Leo Pharma A/S Small molecule modulators of IL-17
US20220162191A1 (en) 2019-03-08 2022-05-26 Leo Pharma A/S Small molecule modulators of il-17
GB201909191D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
GB201909194D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
GB201909190D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
WO2021170627A1 (en) 2020-02-25 2021-09-02 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
WO2021170631A1 (en) 2020-02-25 2021-09-02 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
WO2021204801A1 (en) 2020-04-07 2021-10-14 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
WO2021204800A1 (en) 2020-04-07 2021-10-14 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
JP2023524018A (ja) 2020-04-30 2023-06-08 ヤンセン ファーマシューティカ エヌ．ベー． Ｉｌ－１７の調節因子としてのイミダゾリダジン
JP2023523770A (ja) * 2020-04-30 2023-06-07 ヤンセン ファーマシューティカ エヌ．ベー． Ｉｌ－１７のモジュレーターとしてのイミダゾピリミジン
KR20230016220A (ko) * 2020-05-27 2023-02-01 사노피 Il-17a 조절제
EP4157828A1 (en) 2020-05-27 2023-04-05 Sanofi Il-17a modulators
CN116209664A (zh) 2020-06-12 2023-06-02 利奥制药有限公司 Il-17的小分子调节剂
EP4168400A1 (en) 2020-06-18 2023-04-26 LEO Pharma A/S Small molecule modulators of il-17
WO2021255086A1 (en) 2020-06-18 2021-12-23 Leo Pharma A/S Small molecule modulators of il-17
WO2021255085A1 (en) 2020-06-18 2021-12-23 Leo Pharma A/S Small molecule modulators of il-17
CN113880767B (zh) * 2020-07-04 2023-10-13 成都先导药物开发股份有限公司 一种免疫调节剂
EP3943495A1 (en) 2020-07-24 2022-01-26 Leo Pharma A/S Small molecule modulators of il-17
CN116406267A (zh) 2020-11-09 2023-07-07 Ucb生物制药有限责任公司 作为il-17调节剂的二环丙基甲基衍生物
WO2022096411A1 (en) 2020-11-09 2022-05-12 UCB Biopharma SRL Dicyclopropylmethyl derivatives as il-17 modulators
CA3200594A1 (en) 2020-12-14 2022-06-23 UCB Biopharma SRL Imidazopyridazine derivatives as il-17 modulators
AR126255A1 (es) 2021-07-01 2023-10-04 UCB Biopharma SRL Derivados de imidazotriazina como moduladores de il-17
KR20240045220A (ko) * 2021-07-09 2024-04-05 다이스 알파, 인크. 페닐 아세트아미드 기재 il-17a 조정제 및 그의 용도
WO2023025783A1 (en) 2021-08-23 2023-03-02 Leo Pharma A/S Small molecule modulators of il-17
WO2023111181A1 (en) 2021-12-16 2023-06-22 Leo Pharma A/S Small molecule modulators of il-17
WO2023166172A1 (en) 2022-03-04 2023-09-07 Leo Pharma A/S Small molecule modulators of il-17
WO2023202664A1 (en) * 2022-04-21 2023-10-26 Beigene, Ltd. Small molecule il-17a modulators
GB202210731D0 (en) 2022-07-22 2022-09-07 UCB Biopharma SRL Therapeutic agents

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57102863A (en) * 1980-12-16 1982-06-26 Takeda Chem Ind Ltd Spiroindolinone and its preparation
PL144822B1 (en) * 1984-05-12 1988-07-30 Boehringer Mannheim Gmbh Method of obtaining novel pyrolobenzimidazoles
DE3445669A1 (de) * 1984-12-14 1986-06-19 Boehringer Mannheim Gmbh, 6800 Mannheim Neue pyrrolo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US4835280A (en) * 1985-01-18 1989-05-30 Boehringer Mannheim Gmbh Indoline compounds for synthesis of pharmaceutically active pyrrolobenzimidazoles
DE3803775A1 (de) * 1988-02-09 1989-08-17 Boehringer Mannheim Gmbh Neue substituierte lactame, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
CN1281590C (zh) 2002-11-27 2006-10-25 南京凯衡科贸有限公司 具有抑制血管生成活性的六员氨基酰胺类衍生物
US7129252B2 (en) 2003-06-16 2006-10-31 Guoqing P Chen Six membered amino-amide derivatives an angiogenisis inhibitors
US8236823B2 (en) 2006-10-27 2012-08-07 Amgen Inc. Multi-cyclic compounds and methods of use
US9309313B2 (en) 2008-01-09 2016-04-12 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of ocular inflammatory disorders
WO2013116682A1 (en) 2012-02-02 2013-08-08 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
ES2674451T3 (es) * 2012-02-21 2018-06-29 Merck Patent Gmbh 2-amino-[1,2,4]triazolo[1,5-a] pirazinas 8-sustituidos como inhibidores de la SYK tirosina quinasa e inhibidores de la serina quinasa GCN2
EP2838538B1 (en) 2012-04-20 2017-03-15 Annji Pharmaceutical Co., Ltd. Cyclopropanecarboxylate esters of purine analogues
AU2013314417B2 (en) 2012-09-13 2016-01-21 F. Hoffmann-La Roche Ag 2-oxo-2,3-dihydro-indoles for the treatment of CNS disorders
WO2014066726A2 (en) 2012-10-26 2014-05-01 Ensemble Therapeutics Corporation Compounds for modulating il-17
CA2915622C (en) 2013-06-21 2020-08-18 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
HUE039972T2 (hu) * 2013-08-02 2019-02-28 Pfizer Heterobicikloaril-RORC2-inhibitorok és eljárás alkalmazásukra
US9428515B2 (en) 2014-05-09 2016-08-30 Boehringer Ingelheim International Gmbh Benzimidazole derivatives
CA2975157C (en) * 2015-01-30 2019-09-17 Pfizer Inc. Sulfonamide-substituted indole modulators of rorc2 and methods of use thereof
WO2016120849A1 (en) * 2015-01-30 2016-08-04 Pfizer Inc. Methoxy-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof
WO2017069224A1 (ja) * 2015-10-22 2017-04-27 塩野義製薬株式会社 Ｍｇａｔ２阻害活性を有するスピロ環誘導体

Also Published As

Publication number Publication date
BR112019026678A2 (pt) 2020-06-30
ES2929369T3 (es) 2022-11-28
CN110769821B (zh) 2023-07-07
EP3638227B1 (en) 2022-08-10
EP3638227A1 (en) 2020-04-22
WO2018229079A1 (en) 2018-12-20
CA3064156A1 (en) 2018-12-20
JP7163379B2 (ja) 2022-10-31
US20200138797A1 (en) 2020-05-07
US11052076B2 (en) 2021-07-06
CN110769821A (zh) 2020-02-07
JP2020523418A (ja) 2020-08-06
GB201709456D0 (en) 2017-07-26

Similar Documents

Publication Publication Date Title
EA202090019A1 (ru) Спироциклические индолины в качестве модуляторов il-17
EA201792688A1 (ru) Производные бензоксазинона и его аналоги в качестве модуляторов активности tnf
EA201990665A1 (ru) Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака
EA201401350A1 (ru) Бензимидазолы, модулирующие tnf-альфа
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201790998A1 (ru) Иммуннорегуляторные агенты
EA201791874A1 (ru) Фторированные ингибиторы лизилоксидазоподобного фермента-2 и их применение
NZ735000A (en) Methods for the treatment of abnormal involuntary movement disorders
EA201790734A1 (ru) Конденсированные пентациклические производные имидазола
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
CY1124761T1 (el) Ρυθμιστες της δραστικοτητας του συμπληρωματος
EA201992083A1 (ru) Модуляторы соматостатина и их применения
EA201692049A1 (ru) Гетероарилзамещенные гетероциклилсульфоны
EA201790519A1 (ru) Терапевтические соединения в качестве ингибиторов рецептора орексина-1
EA201990400A1 (ru) Соединения и композиции и их применение
EA202091020A1 (ru) Замещенные имидазопиридинамиды и их применение
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
EA201990915A1 (ru) Новые модуляторы 5-гидрокситриптаминового рецептора 7 и способ их применения
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MD3416631T2 (ro) Agenți terapeutici pentru bolile neurodegenerative
EA201792686A1 (ru) Производные индазола в качестве модуляторов активности tnf
EA201792575A1 (ru) Фармацевтические композиции леветирацетама пролонгированного высвобождения
EA201792610A1 (ru) Способ лечения неврологического заболевания
EA201892153A1 (ru) Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf